MTOR and neoplasm: AKT3, a core member of the PI3K-AKT-mTOR pathway, can inhibit immune responses through multiple pathways: promoting the infiltration of regulatory T cells (Tregs), inhibiting the maturation of dendritic cells (DCs), and reducing the cytotoxicity of tumor-infiltrating lymphocytes.